38360761|t|Prevalence, distribution, and severity of cerebral amyloid angiopathy differ between Lewy body diseases and Alzheimer's disease.
38360761|a|Dementia with Lewy bodies (DLB), Parkinson's disease dementia (PDD), and Parkinson's disease (PD) collectively known as Lewy body diseases (LBDs) are neuropathologically characterised by alpha-synuclein deposits (Lewy bodies and Lewy neurites). However, LBDs also exhibit pathology associated with Alzheimer's disease (AD) (i.e. hyperphosphorylated tau and amyloid beta (Abeta). Abeta can be deposited in the walls of blood vessels in the brains of individuals with AD, termed cerebral amyloid angiopathy (CAA). The aim of this study was to investigate the type and distribution of CAA in DLB, PDD, and PD and determine if this differs from AD. CAA type, severity, and topographical distribution was assessed in 94 AD, 30 DLB, 17 PDD, and 11 PD cases, and APOE genotype evaluated in a subset of cases where available. 96.3% AD cases, 70% DLB cases and 82.4% PDD cases exhibited CAA (type 1 or type 2). However only 45.5% PD cases had CAA. Type 1 CAA accounted for 37.2% of AD cases, 10% of DLB cases, and 5.9% of PDD cases, and was not observed in PD cases. There was a hierarchical topographical distribution in regions affected by CAA where AD and DLB displayed the same distribution pattern that differed from PDD and PD. APOE epsilon4 was associated with severity of CAA in AD cases. Topographical patterns and severity of CAA in DLB more closely resembled AD rather than PDD, and as type 1 CAA is associated with clinical dementia in AD, further investigations are warranted into whether the increased presence of type 1 CAA in DLB compared to PDD are related to the onset of cognitive symptoms and is a distinguishing factor between LBDs. Possible alignment of the the topographical distribution of CAA and microbleeds in DLB warrants further investigation. CAA in DLB more closely resembles AD rather than PDD or PD, and should be taken into consideration when stratifying patients for clinical trials or designing disease modifying therapies.
38360761	42	69	cerebral amyloid angiopathy	Disease	MESH:D016657
38360761	85	103	Lewy body diseases	Disease	MESH:D020961
38360761	108	127	Alzheimer's disease	Disease	MESH:D000544
38360761	129	154	Dementia with Lewy bodies	Disease	MESH:D020961
38360761	156	159	DLB	Disease	MESH:D020961
38360761	162	190	Parkinson's disease dementia	Disease	MESH:D010300
38360761	192	195	PDD	Disease	MESH:D010300
38360761	202	221	Parkinson's disease	Disease	MESH:D010300
38360761	223	225	PD	Disease	MESH:D010300
38360761	249	267	Lewy body diseases	Disease	MESH:D020961
38360761	269	273	LBDs	Disease	MESH:D020961
38360761	316	331	alpha-synuclein	Gene	6622
38360761	342	353	Lewy bodies	Disease	MESH:D020961
38360761	358	371	Lewy neurites	Disease	MESH:D058225
38360761	383	387	LBDs	Disease	MESH:D020961
38360761	427	446	Alzheimer's disease	Disease	MESH:D000544
38360761	448	450	AD	Disease	MESH:D000544
38360761	478	481	tau	Gene	4137
38360761	486	498	amyloid beta	Gene	351
38360761	500	505	Abeta	Gene	351
38360761	508	513	Abeta	Gene	351
38360761	595	597	AD	Disease	MESH:D000544
38360761	606	633	cerebral amyloid angiopathy	Disease	MESH:D016657
38360761	635	638	CAA	Disease	MESH:D016657
38360761	711	714	CAA	Disease	MESH:D016657
38360761	718	721	DLB	Disease	MESH:D020961
38360761	723	726	PDD	Disease	MESH:D010300
38360761	732	734	PD	Disease	MESH:D010300
38360761	770	772	AD	Disease	MESH:D000544
38360761	774	777	CAA	Disease	MESH:D016657
38360761	844	846	AD	Disease	MESH:D000544
38360761	851	854	DLB	Disease	MESH:D020961
38360761	859	862	PDD	Disease	MESH:D010300
38360761	871	873	PD	Disease	MESH:D010300
38360761	885	889	APOE	Gene	348
38360761	953	955	AD	Disease	MESH:D000544
38360761	967	970	DLB	Disease	MESH:D020961
38360761	987	990	PDD	Disease	MESH:D010300
38360761	1007	1029	CAA (type 1 or type 2)	Disease	MESH:D016657
38360761	1050	1052	PD	Disease	MESH:D010300
38360761	1063	1066	CAA	Disease	MESH:D016657
38360761	1075	1078	CAA	Disease	MESH:D016657
38360761	1102	1104	AD	Disease	MESH:D000544
38360761	1119	1122	DLB	Disease	MESH:D020961
38360761	1142	1145	PDD	Disease	MESH:D010300
38360761	1177	1179	PD	Disease	MESH:D010300
38360761	1262	1265	CAA	Disease	MESH:D016657
38360761	1272	1274	AD	Disease	MESH:D000544
38360761	1279	1282	DLB	Disease	MESH:D020961
38360761	1342	1345	PDD	Disease	MESH:D010300
38360761	1350	1352	PD	Disease	MESH:D010300
38360761	1354	1358	APOE	Gene	348
38360761	1400	1403	CAA	Disease	MESH:D016657
38360761	1407	1409	AD	Disease	MESH:D000544
38360761	1456	1459	CAA	Disease	MESH:D016657
38360761	1463	1466	DLB	Disease	MESH:D020961
38360761	1490	1492	AD	Disease	MESH:D000544
38360761	1505	1508	PDD	Disease	MESH:D010300
38360761	1524	1527	CAA	Disease	MESH:D016657
38360761	1556	1564	dementia	Disease	MESH:D003704
38360761	1568	1570	AD	Disease	MESH:D000544
38360761	1655	1658	CAA	Disease	MESH:D016657
38360761	1662	1665	DLB	Disease	MESH:D020961
38360761	1678	1681	PDD	Disease	MESH:D010300
38360761	1710	1719	cognitive	Disease	MESH:D003072
38360761	1768	1772	LBDs	Disease	MESH:D020961
38360761	1834	1837	CAA	Disease	MESH:D016657
38360761	1842	1853	microbleeds	Disease	
38360761	1857	1860	DLB	Disease	MESH:D020961
38360761	1893	1896	CAA	Disease	MESH:D016657
38360761	1900	1903	DLB	Disease	MESH:D020961
38360761	1927	1929	AD	Disease	MESH:D000544
38360761	1942	1945	PDD	Disease	MESH:D010300
38360761	1949	1951	PD	Disease	MESH:D010300
38360761	2009	2017	patients	Species	9606
38360761	Association	MESH:D020961	351
38360761	Association	MESH:D000544	351
38360761	Association	MESH:D016657	351
38360761	Association	MESH:D020961	6622

